Hydrochlorothiazide + Spironolactone Side Effects & Health Impacts

Low folate status contributes to elevated homocysteine, a metabolite that has been associated with endothelial dysfunction, arterial stiffness, and a higher risk of stroke and coronary heart disease. Large observational studies consistently show that individuals with higher homocysteine levels have greater rates of cardiovascular events, and folate intake is one of the key nutritional determinants of homocysteine. Clinically, folic acid supplementation (often combined with vitamins B6 and B12) can lower homocysteine and appears to modestly reduce stroke risk in some populations, making the identification and correction of folate deficiency an important part of broader cardiovascular risk reduction.

Research: Yanping Li, et al. Folic Acid Supplementation and the Risk of Cardiovascular Diseases: A Meta‐Analysis of Randomized Controlled Trials. Journal of the American Heart Association. Volume 5, Number 8. August 15 2016.Yi X, Zhou Y, Jiang D, Li X, Guo Y, Jiang X. Efficacy of folic acid supplementation on endothelial function and plasma homocysteine concentration in coronary artery disease: A meta-analysis of randomized controlled trials. Exp Ther Med. 2014 May;7(5):1100-1110. Kaye AD, Jeha GM, Pham AD, Fuller MC, Lerner ZI, Sibley GT, Cornett EM, Urits I, Viswanath O, Kevil CG. Folic Acid Supplementation in Patients with Elevated Homocysteine Levels. Adv Ther. 2020 Oct;37(10):4149-4164. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J Jr; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006 Apr 13;354(15):1567-77. Wald DS, Bishop L, Wald NJ, et al. Randomized Trial of Folic Acid Supplementation and Serum Homocysteine Levels. Arch Intern Med. 2001;161(5):695–700.

Low or depleted magnesium levels are associated with a higher likelihood of several cardiovascular problems, including arrhythmias, where people with low magnesium have been shown to have 2–4 times higher odds of these rhythm disturbances compared with those with normal levels. Low magnesium is also linked to worsening coronary artery disease, progression of heart failure, and development or aggravation of hypertension, driven by disrupted cardiac electrical stability, vascular function, and electrolyte balance. Even mild magnesium depletion may contribute to higher blood pressure over time, adding to the overall cardiovascular burden, especially in individuals with existing heart disease or multiple risk factors.

Research: Kolte D, Vijayaraghavan K, Khera S, Sica DA, Frishman WH. Role of magnesium in cardiovascular diseases. Cardiol Rev. 2014 Jul-Aug;22(4):182-92. Vierling W, Liebscher DH, Micke O, von Ehrlich B, Kisters K. Magnesium deficiency and therapy in cardiac arrhythmias: recommendations of the German Society for Magnesium Research. Dtsch Med Wochenschr. 2013 May;138(22):1165-71. Houston M. The role of magnesium in hypertension and cardiovascular disease. J Clin Hypertens (Greenwich). 2011 Nov;13(11):843-7. Yin Y, Costello RB, Fonarow GC, Heidenreich PA, Morgan CJ, Faselis C, Cheng Y, Zullo AR, Liu S, Lam PH, Rosanoff A, Vargas JD, Gottlieb SS, Deedwania P, Moore HJ, Shao Y, Sheriff HM, Wu WC, Zeng-Treitler Q, Ahmed A. Oral magnesium and outcomes in US veterans with heart failure. Eur Heart J. 2026 Jan 5;47(1):80-90.

Potassium deficiency can destabilize the heart’s electrical system, so hypokalemia is a well‑known trigger for cardiac arrhythmias and can present with palpitations, “skipped beats,” or more dangerous rhythm disturbances even before other symptoms are obvious. As serum potassium drops, characteristic ECG changes (flattened or inverted T waves, ST‑segment depression, prominent U waves, and QT‑interval prolongation) reflect impaired repolarization, which can progress to premature ventricular contractions, atrial fibrillation, ventricular tachycardia, torsade de pointes, or even ventricular fibrillation and cardiac arrest in severe cases. Observational data show that hypokalemia and even low‑normal potassium levels increase the risk of ventricular arrhythmias and sudden cardiac death in people with underlying heart disease, highlighting the importance of monitoring and promptly correcting potassium deficits in hospitalized and high‑risk patients.

Research: Krijthe BP, Heeringa J, Kors JA, Hofman A, Franco OH, Witteman JC, Stricker BH. Serum potassium levels and the risk of atrial fibrillation: the Rotterdam Study. Int J Cardiol. 2013 Oct 15;168(6):5411-5.Jeejeebhoy KN, Chu RC, Marliss EB, Greenberg GR, Bruce-Robertson A. Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation, in a patient receiving long-term total parenteral nutrition. Am J Clin Nutr. 1977 Apr;30(4):531-8. Wang XD, Wang Y, Liu J, Yao JW, Zhang J, Zhang YN. Prognosis of Older Adult Patients Suffering from Atrial Fibrillation and Hypokalemia. Clin Interv Aging. 2023;18:1363-1371. Federico Bernardo Rossi, Ambra Sammarco, Teresa Maria Seccia, Potassium and aldosterone as determinants of new-onset atrial fibrillation, European Heart Journal, 2026.

Folate deficiency in the periconceptional period significantly increases the risk of neural tube defects (NTDs) such as spina bifida and anencephaly, because adequate folate is required for proper closure of the embryonic neural tube in the first month of pregnancy. Large observational datasets and randomized trials have shown that appropriate folic acid supplementation before conception and in early pregnancy can reduce NTD risk by roughly 50–70% in the general population, with even greater risk reduction in women with a prior NTD‑affected pregnancy. The practical implication is that all women of childbearing potential, not just those actively planning pregnancy, are typically advised to maintain adequate daily folic acid intake so that red‑cell folate stores are sufficient well before conception occurs.

Research: Viswanathan M, Urrutia RP, Hudson KN, Middleton JC, Kahwati LC. Folic Acid Supplementation to Prevent Neural Tube Defects: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2023;330(5):460–466. Wald NJ. Folic acid and neural tube defects: Discovery, debate and the need for policy change. J Med Screen. 2022 Sep;29(3):138-146. Mathieu d'Argent E, Ravel C, Rousseau A, Morcel K, Massin N, Sussfeld J, Simon T, Antoine JM, Mandelbaume J, Daraï E, Kolanska K. High-Dose Supplementation of Folic Acid in Infertile Men Improves IVF-ICSI Outcomes: A Randomized Controlled Trial (FOLFIV Trial). J Clin Med. 2021 Apr 26;10(9):1876. Jadhav, S. N., & Pitale, D. L. (2020). Effectiveness of folic acid in unexplained infertility. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 9(9), 3780–3783.

CoQ10 deficiency can present in infancy as a severe encephalomyopathy or multisystemic mitochondrial disease, with features such as hypotonia, developmental delay, intractable seizures, lactic acidosis, cardiomyopathy, and failure to thrive. Reports of infantile‑onset multisystem CoQ10 deficiency describe very early presentations, sometimes in the neonatal period, with rapid neurologic deterioration and involvement of brain, heart, kidney, and liver, and many affected children die in the first months or years of life despite intensive care. The important clinical point is that, although outcomes are often poor in the most severe cases, some infants and young children show neurologic improvement or stabilization when CoQ10 deficiency is recognized early and high‑dose CoQ10 supplementation is started promptly, which is why this diagnosis is considered a treatable cause of infantile encephalomyopathy

Research: Quinzii CM, Hirano M. Coenzyme Q and mitochondrial disease. Dev Disabil Res Rev. 2010;16(2):183-8. Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur Neurol. 1997;37(4):212-8. Boitier E, Degoul F, Desguerre I, Charpentier C, François D, Ponsot G, Diry M, Rustin P, Marsac C. A case of mitochondrial encephalomyopathy associated with a muscle coenzyme Q10 deficiency. J Neurol Sci. 1998;156(1):41-6. Sobreira C, Hirano M, Shanske S, Keller RK, Haller RG, Davidson E, Santorelli FM, Miranda AF, Bonilla E, Mojon DS, Barreira AA, King MP, DiMauro S. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency. Neurology. 1997 May;48(5):1238-43.

CoQ10 is a key mitochondrial antioxidant, and circulating levels are often reduced in people with chronic kidney disease and chronic heart failure, where deficiency is linked to greater oxidative stress and poorer organ function. In CKD cohorts, lower CoQ10 levels correlate with increased cardiovascular risk, and supplementation has been reported to improve markers such as proteinuria, mitochondrial function, and oxidative stress, with some studies suggesting better preservation of kidney function over time. In patients with chronic heart failure, trials such as Q-SYMBIO have shown that CoQ10 supplementation can improve cardiac function parameters and significantly reduce major adverse cardiovascular events, cardiovascular mortality, and heart‑failure–related hospitalizations.

Research: Xu Y, Liu J, Han E, Wang Y, Gao J. Efficacy of coenzyme Q10 in patients with chronic kidney disease: protocol for a systematic review. BMJ Open. 2019 May 14;9(5):e029053. Bakhshayeshkaram M, Lankarani KB, Mirhosseini N, Tabrizi R, Akbari M, Dabbaghmanesh MH, Asemi Z. The Effects of Coenzyme Q10 Supplementation on Metabolic Profiles of Patients with Chronic Kidney Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Curr Pharm Des. 2018;24(31):3710-3723. Di Lorenzo A, Iannuzzo G, Parlato A, Cuomo G, Testa C, Coppola M, D'Ambrosio G, Oliviero DA, Sarullo S, Vitale G, Nugara C, Sarullo FM, Giallauria F. Clinical Evidence for Q10 Coenzyme Supplementation in Heart Failure: From Energetics to Functional Improvement. J Clin Med. 2020 Apr 27;9(5):1266. DiNicolantonio JJ, Bhutani J, McCarty MF, O'Keefe JH. Coenzyme Q10 for the treatment of heart failure: a review of the literature. Open Heart. 2015;2:e000326.

Low or depleted magnesium levels place people with diabetes and metabolic syndrome (MetSyn) at higher risk of worsening glycemic control and insulin resistance because magnesium is essential for normal glucose metabolism and beta-cell function. When magnesium is low, these metabolic pathways become less efficient, amplifying blood sugar instability, lipid abnormalities, and other MetSyn features. Even moderate depletion can accelerate type 2 diabetes and MetSyn-related complications, underscoring the need for monitoring magnesium status in these vulnerable groups.

Research: Gommers LM, Hoenderop JG, Bindels RJ, de Baaij JH. Hypomagnesemia in Type 2 Diabetes: A Vicious Circle? Diabetes. 2016 Jan;65(1):3-13. Ozcaliskan Ilkay H, Sahin H, Tanriverdi F, Samur G. Association Between Magnesium Status, Dietary Magnesium Intake, and Metabolic Control in Patients with Type 2 Diabetes Mellitus. J Am Coll Nutr. 2019 Jan;38(1):31-39. Mooren FC. Magnesium and disturbances in carbohydrate metabolism. Diabetes Obes Metab. 2015 Sep;17(9):813-23. Paladiya R, Pitliya A, Choudhry AA, Kumar D, Ismail S, Abbas M, Naz S, Kumar B, Jamil A, Fatima A. Association of Low Magnesium Level With Duration and Severity of Type 2 Diabetes. Cureus. 2021 May 27;13(5):e15279. Ju SY, Choi WS, Ock SM, Kim CM, Kim DH. Dietary magnesium intake and metabolic syndrome in the adult population: dose-response meta-analysis and meta-regression. Nutrients. 2014 Dec 22;6(12):6005-19.

Low or depleted magnesium levels are associated with a higher risk of osteoporosis and fractures, with studies linking magnesium deficiency to a 25–35% increased risk of hip, wrist, and spine fractures in some populations. Magnesium deficiency impairs bone mineralization and vitamin D activation, compounding skeletal weakness by disrupting osteoblast function and calcium balance. This is particularly concerning for older adults or those with additional risk factors, where monitoring magnesium status and considering supplementation may help mitigate bone loss.

Research: Front Pharmacol. 2025 May 12;16:1592048. Rude RK, Singer FR, Gruber HE. Skeletal and hormonal effects of magnesium deficiency. J Am Coll Nutr. 2009 Apr;28(2):131-41. Liu L, Luo P, Wen P, Xu P. The role of magnesium in the pathogenesis of osteoporosis. Front Endocrinol (Lausanne). 2024 Jun 6;15:1406248. Li S, Chang W, Wu G, Wang K, Sun X, Sun H, Zhou J. Association between magnesium deficiency scores and hip bone health in adults: a population-based study. Magnes Res. 2025 Dec 1;38(3):81-94. Belluci MM, de Molon RS, Rossa C Jr, Tetradis S, Giro G, Cerri PS, Marcantonio E Jr, Orrico SRP. Severe magnesium deficiency compromises systemic bone mineral density and aggravates inflammatory bone resorption. J Nutr Biochem. 2020 Mar;77:108301.

Magnesium depletion can contribute to neurological issues like migraines, depression, seizures, and cognitive impairment by disrupting neuronal excitability, neurotransmitter balance, and NMDA receptor function. Case reports often describe severe symptoms such as tremors, encephalopathy, cerebellar ataxia, or memory problems in affected patients, which typically resolve once magnesium levels are restored. Although these effects occur less frequently than cardiovascular complications, monitoring is advisable particularly in older adults with persistent low magnesium.

Research: Chen F, Wang J, Cheng Y, Li R, Wang Y, Chen Y, Scott T, Tucker KL. Magnesium and Cognitive Health in Adults: A Systematic Review and Meta-Analysis. Adv Nutr. 2024 Aug;15(8):100272. Kumar A, Mehan S, Tiwari A, Khan Z, Gupta GD, Narula AS, Samant R. Magnesium (Mg2+): Essential Mineral for Neuronal Health: From Cellular Biochemistry to Cognitive Health and Behavior Regulation. Curr Pharm Des. 2024;30(39):3074-3107. Varga P, Lehoczki A, Fekete M, Jarecsny T, Kryczyk-Poprawa A, Zábó V, Major D, Fazekas-Pongor V, Csípő T, Varga JT. The Role of Magnesium in Depression, Migraine, Alzheimer's Disease, and Cognitive Health: A Comprehensive Review. Nutrients. 2025 Jul 4;17(13):2216. Mauskop A, Varughese J. Why all migraine patients should be treated with magnesium. J Neural Transm (Vienna). 2012 May;119(5):575-9.

Potassium deficiency can progress from diffuse muscle weakness to flaccid paralysis, and in severe hypokalemia this paralysis may involve the diaphragm and other respiratory muscles, resulting in hypoventilation and acute respiratory failure. In these situations, patients often present with ascending weakness, areflexia, and shortness of breath or an inability to take a deep breath, and may require urgent ventilatory support while intravenous potassium is carefully replaced. Case reports and cohort data show that even admission potassium values just below the normal range are associated with a higher risk of needing mechanical ventilation in hospitalized patients, underscoring the importance of promptly recognizing and correcting hypokalemia before it reaches paralysis‑level severity.

Research: Haddad S, Arabi Y, Shimemeri AA. Hypokalemic paralysis mimicking Guillain-Barré syndrome and causing acute respiratory failure. Middle East J Anaesthesiol. 2004 Jun;17(5):891-7. PMID: 15449746. Wu CZ, Wu YK, Lin JD, Kuo SW. Thyrotoxic periodic paralysis complicated by acute hypercapnic respiratory failure and ventricular tachycardia. Thyroid. 2008 Dec;18(12):1321-4. Ayyawar H, et al. Hypokalemic Paralysis Leading to Respiratory Failure: An Unusual Presentation of Sjogren’s Syndrome. Austin Crit Care Case Rep. 2021; 5(3): 1030. Sobrosa P Sr, Ferreira Â, Vilar da Mota R, Couto J, Sousa L. Severe Hypokalemia and Respiratory Muscle Paralysis: An Atypical Manifestation of Primary Sjögren's Syndrome. Cureus. 2024 Dec 23;16(12):e76240.

Potassium deficiency can contribute to hypertension because low potassium intake and chronically low‑normal serum levels make blood vessels less able to relax and enhance the blood‑pressure‑raising effects of dietary sodium. Epidemiologic studies and feeding trials show that people with lower urinary potassium excretion tend to have higher blood pressure, and that short periods on a low‑potassium diet can raise systolic and diastolic pressure compared with a higher‑potassium diet of similar calories and sodium. In contrast, restoring potassium—whether through diet or supplements in appropriate patients—has been shown to lower blood pressure, reduce the need for antihypertensive medication, and is associated with a lower risk of stroke, highlighting that potassium deficiency is a modifiable driver of high blood pressure rather than just a lab abnormality.

Research: Jun HJ, Kim S, Jo G. Age-period-cohort analysis of dietary sodium, potassium, and sodium-to-potassium ratio in Korea. Epidemiol Health. 2025;47:e2025062. Ziaei R, Askari G, Foshati S, Zolfaghari H, Clark CCT, Rouhani MH. Association between urinary potassium excretion and blood pressure: A systematic review and meta-analysis of observational studies. J Res Med Sci. 2020 Dec 30;25:116. Granal M, Sourd V, Burnier M, Fauvel JP, Gougeon A. Effect of changes in potassium intake on blood pressure: a dose-response meta-analysis of randomized clinical trials (2000-2024). Clin Kidney J. 2025 Jun 28;18(7):sfaf173. Duan, Li Qin, et al. Study on the Correlation between Urinary Sodium and Potassium Excretion and Blood Pressure in Adult Hypertensive Inpatients of Different Sexes, International Journal of Clinical Practice, 2022, 1854475, 8 pages, 2022.

Low zinc status has been linked to a higher risk and faster progression of age-related macular degeneration (AMD), in part because zinc is concentrated in the retina and supports antioxidant defenses there. In the landmark AREDS trial, a supplement formula containing zinc (80 mg as zinc oxide), along with antioxidants, reduced the risk of progression to advanced AMD by about 25% in people with intermediate disease or advanced disease in one eye over roughly 5 years. Other research has shown that inadequate zinc intake is more common in older adults with AMD, reinforcing the idea that maintaining healthy zinc levels may be an important, and often overlooked, strategy for preserving macular health with age.

Research: Smailhodzic D, van Asten F, Blom AM, Mohlin FC, den Hollander AI, van de Ven JPH, et al. (2014) Zinc Supplementation Inhibits Complement Activation in Age-Related Macular Degeneration. PLoS ONE 9(11): e112682. Lengyel D, Török B. Erworbene vorübergehende Nachtblindheit bei Vitamin-A- und Zinkmangel bei Anorexia nervosa neun Jahre nach Nierentransplantation [Acquired temporary night blindness in vitamin A and zinc deficiency in anorexia nervosa nine years after kidney transplantation]. Klin Monbl Augenheilkd. 2006 May;223(5):453-5. German.Blasiak J, Pawlowska E, Chojnacki J, Szczepanska J, Chojnacki C, Kaarniranta K. Zinc and Autophagy in Age-Related Macular Degeneration. Int J Mol Sci. 2020 Jul 15;21(14):4994. Benjamin P. Nicholson, et al. Chapter 37 - Zinc Deficiency and the Eye. Handbook of Nutrition, Diet and the Eye 2014, Pages 371-376.

In older adults, low folate status has been associated with a higher risk of mild cognitive impairment (MCI) and faster cognitive decline over time, likely through effects on one‑carbon metabolism and homocysteine. Several longitudinal cohort studies have found that individuals with lower serum or red‑cell folate and higher homocysteine show steeper declines on memory and global cognition tests, and in some cohorts have a significantly higher incidence of MCI or dementia over follow‑up. The clinically important takeaway is that, when folate deficiency is detected and corrected (usually along with ensuring adequate vitamin B12), some patients demonstrate stabilization or modest improvement in cognitive performance, particularly when interventions are combined with aggressive management of vascular risk factors such as hypertension and diabetes.

Research: Ma, F., Wu, T., Zhao, J. et al. Folic acid supplementation improves cognitive function by reducing the levels of peripheral inflammatory cytokines in elderly Chinese subjects with MCI. Sci Rep 6, 37486 (2016). Wang M, Fang M, Zang W. Effects of folic acid supplementation on cognitive function and inflammation in elderly patients with mild cognitive impairment: A systematic review and meta-analysis of randomized controlled trials. Arch Gerontol Geriatr. 2024 Nov;126:105540. O’Connor, D.M.A., Scarlett, S., De Looze, C. et al. Low folate predicts accelerated cognitive decline: 8-year follow-up of 3140 older adults in Ireland. Eur J Clin Nutr 76, 950–957 (2022).Putu Eka Widyadharma. Folic acid supplementation improves cognitive function: A systematic review. December 2020 Romanian Journal of Neurology 19(4):219-223.

CoQ10 deficiency has been identified as a potentially reversible cause of steroid‑resistant nephrotic syndrome and glomerular nephropathy, particularly in children and young adults with genetic defects in CoQ10 biosynthesis. In reported series, affected patients often present with heavy proteinuria and progressive kidney dysfunction that fail to respond to standard steroid therapy, but genetic testing sometimes reveals mutations in CoQ10‑related genes (such as COQ2, COQ6, or ADCK4). The encouraging part is that in a subset of these cases, early and sufficiently dosed CoQ10 supplementation has been associated with reduced proteinuria and stabilization or partial improvement of kidney function, making it an important, treatable consideration in otherwise unexplained steroid‑resistant nephrotic syndrome.

Research: Frehat MQ Sr, Alhadidi A, Almheairat A, Alkhatib L, Al Thaher S, Al Assaf R, Al Qawaqenah M, Mansour B, Khair F. Success of Coenzyme Q10 in Treating Steroid-Resistant Nephrotic Syndrome in Jordan: A Case Series. Cureus. 2025 Apr 30;17(4):e83231. Drovandi S, Lipska-Ziętkiewicz BS, Ozaltin F, et al. Oral Coenzyme Q10 supplementation leads to better preservation of kidney function in steroid-resistant nephrotic syndrome due to primary Coenzyme Q10 deficiency. Kidney Int. 2022 Sep;102(3):604-612. Drovandi S, Lipska-Ziętkiewicz BS, et al. Variation of the clinical spectrum and genotype-phenotype associations in Coenzyme Q10 deficiency associated glomerulopathy. Kidney Int. 2022 Sep;102(3):592-603. Salviati L, Sacconi S, Murer L, Zacchello G, Franceschini L, Laverda AM, Basso G, Quinzii C, Angelini C, Hirano M, Naini AB, Navas P, DiMauro S, Montini G. Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology. 2005 Aug 23;65(4):606-8.

In some children and young adults, primary CoQ10 deficiency has been linked to hypertrophic cardiomyopathy (HCM), where the heart muscle becomes abnormally thick and stiff despite the absence of more common causes like longstanding hypertension. Case series and reports describe patients with genetically confirmed CoQ10 biosynthetic defects who develop HCM alongside other mitochondrial features such as exercise intolerance, muscle weakness, or neurologic symptoms, and cardiac imaging often shows concentric or asymmetric left ventricular hypertrophy. The hopeful aspect is that early recognition and CoQ10 supplementation have, in some documented cases, led to improved cardiac function or stabilization of wall thickness over time, making CoQ10 deficiency a particularly important and potentially treatable consideration in otherwise unexplained or familial‑appearing HCM.

Research: Adarsh K, Kaur H, Mohan V. Coenzyme Q10 (CoQ10) in isolated diastolic heart failure in hypertrophic cardiomyopathy (HCM). Biofactors. 2008;32(1-4):145-9. Sharma A, Fonarow GC, Butler J, Ezekowitz JA, Felker GM. Coenzyme Q10 and Heart Failure: A State-of-the-Art Review. Circ Heart Fail. 2016 Apr;9(4):e002639. Sondheimer N, Hewson S, Cameron JM, Somers GR, Broadbent JD, Ziosi M, Quinzii CM, Naini AB. Novel recessive mutations in COQ4 cause severe infantile cardiomyopathy and encephalopathy associated with CoQ10 deficiency. Mol Genet Metab Rep. 2017 May 11;12:23-27. Smet J, De Meirleir L. Early myoclonic epilepsy, hypertrophic cardiomyopathy and subsequently a nephrotic syndrome in a patient with CoQ10 deficiency caused by mutations in para-hydroxybenzoate-polyprenyl transferase (COQ2). Eur J Paediatr Neurol. 2013 Nov;17(6):625-30.

Impacted through 2 nutrients: Magnesium, Potassium.

Potassium deficiency can set the stage for rhabdomyolysis, a severe form of muscle breakdown, because chronically low potassium impairs normal muscle metabolism, contraction, and blood-flow regulation during exertion. In potassium‑depleted muscle, exercise normally meant to trigger local potassium‑mediated vasodilation instead occurs on a background of blunted blood‑flow increase and relative ischemia, which can tip active fibers toward cramps, fiber necrosis, and release of muscle enzymes such as creatine kinase and myoglobin. Case reports describe patients with profound hypokalemia from causes like primary aldosteronism, short‑bowel–related losses, or periodic paralysis presenting with weakness, dark “cola‑colored” urine, and very high creatine kinase levels, often improving after aggressive potassium repletion and hydration, highlighting that low potassium can be a hidden, correctable driver of non‑traumatic rhabdomyolysis.

Research: Jain VV, Gupta OP, Jajoo SU, Khiangate B. Hypokalemia induced rhabdomyolysis. Indian J Nephrol. 2011 Jan;21(1):66. Chung-Tso Chen, et al. Hypokalemia-Induced Rhabdomyolysis Caused by Adrenal Tumor-Related Primary Aldosteronism: A Report of 2 Cases. Am J Case Rep 2021; 22:e929758. He R, Guo WJ, She F, Miao GB, Liu F, Xue YJ, Liu YW, Wang HT, Zhang P. A rare case of hypokalemia-induced rhabdomyolysis. J Geriatr Cardiol. 2018 Apr;15(4):321-324. Dimitrios J. Antoniadis, et al. Rhabdomyolysis Due to Diuretic Treatment. Hellenic J Cardiol 44: 80-82, 2003.

When potassium levels remain low, potassium deficiency can quietly worsen insulin sensitivity, contributing to insulin resistance and impaired glucose tolerance even in people without obvious diabetes. Clinically, hypokalemia has been associated with higher fasting glucose and insulin levels, and with a greater risk of developing new‑onset diabetes in patients on potassium‑wasting diuretics compared with those whose potassium is better maintained. The encouraging piece is that correcting low potassium, alongside other lifestyle and medical strategies, can improve insulin action and glycemic control in some individuals, suggesting that unrecognized potassium deficiency may be a modifiable piece of the insulin‑resistance puzzle.

Research: Plavinik FL, Rodrigues CI, Zanella MT, Ribeiro AB. Hypokalemia, glucose intolerance, and hyperinsulinemia during diuretic therapy. Hypertension. 1992 Feb;19(2 Suppl):II26-9. Phillip Gorden; Glucose Intolerance with Hypokalemia: Failure of Short-term Potassium Depletion in Normal Subjects to Reproduce the Glucose and Insulin Abnormalities of Clinical Hypokalemia. Diabetes 1 July 1973; 22 (7): 544–551. Heianza Y, Hara S, Arase Y, Saito K, Totsuka K, Tsuji H, Kodama S, Hsieh SD, Yamada N, Kosaka K, Sone H. Low serum potassium levels and risk of type 2 diabetes: the Toranomon Hospital Health Management Center Study 1 (TOPICS 1). Diabetologia. 2011 Apr;54(4):762-6. Chatterjee R, Yeh HC, Shafi T, Selvin E, Anderson C, Pankow JS, Miller E, Brancati F. Serum and dietary potassium and risk of incident type 2 diabetes mellitus: The Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2010 Oct 25;170(19):1745-51.

Impacted through 2 nutrients: Zinc, Folic Acid.

Closely linked to reproductive and hormonal problems in both men and women, zinc deficiency can contribute to hypogonadism, low testosterone, reduced sperm count, and menstrual irregularities. In men, low zinc status has been associated with decreased serum testosterone, reduced sperm density and motility, and poorer overall semen quality, while zinc repletion in deficient individuals has been shown to improve some of these parameters. In women, inadequate zinc intake is tied to more frequent cycle disturbances, dysmenorrhea, and potential impacts on ovulation and fertility, underscoring zinc’s important role in healthy hormonal balance and reproductive function.

Research: Zhao J, Dong X, Hu X, Long Z, Wang L, Liu Q, Sun B, Wang Q, Wu Q, Li L. Zinc levels in seminal plasma and their correlation with male infertility: A systematic review and meta-analysis. Sci Rep. 2016 Mar 2;6:22386. Mohan H, Verma J, Singh I, Mohan P, Marwah S, Singh P. Inter-relationship of zinc levels in serum and semen in oligospermic infertile patients and fertile males. Indian J Pathol Microbiol. 1997 Oct;40(4):451-5. PMID: 9444854. Zečević N, Veselinović A, Perović M, Stojsavljević A. Association Between Zinc Levels and the Impact of Its Deficiency on Idiopathic Male Infertility: An Up-to-Date Review. Antioxidants (Basel). 2025 Jan 29;14(2):165. Dhar S, Yadav R, Tomar A. Serum Zinc Levels in Women with Polycystic Ovarian Syndrome are Lower as Compared to Those without Polycystic Ovarian Syndrome: A Cohort Study. J Hum Reprod Sci. 2024 Jan-Mar;17(1):25-32.

In pregnancy, inadequate folate status not only increases neural tube defect risk but is also associated with maternal megaloblastic anemia, which can worsen fatigue, reduce exercise tolerance, and increase the likelihood of transfusion around delivery. Observational studies have linked low folate and elevated homocysteine with a higher risk of miscarriage, placental complications, and low birth weight, and some data suggest that suboptimal folate status may contribute to certain infertility contexts, particularly when combined with other nutritional or metabolic stressors. The clinical takeaway is that maintaining sufficient folate intake before conception and throughout pregnancy is a key strategy to reduce anemia and support healthier fertility and pregnancy outcomes beyond neural tube defect prevention.

Research: Murto, T. et al. Folic acid supplementation and IVF pregnancy outcome in women with unexplained infertility. Dey M, Dhume P, Sharma SK, Goel S, Chawla S, Shah A, Madhumidha G, Rawal R. Folic acid: The key to a healthy pregnancy - A prospective study on fetomaternal outcome. Tzu Chi Med J. 2023 Oct 31;36(1):98-102. Hariz A, Bhattacharya PT. Megaloblastic Anemia. [Updated 2023 Apr 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan. Lazar VMA, Rahman S, Chowdhury NH, Hasan T, Akter S, Islam MS, Ahmed S, Baqui AH, Khanam R. Folate deficiency in pregnancy and the risk of preterm birth: A nested case-control study. J Glob Health. 2024 Jul 12;14:04120. Zheng J-S, Guan Y, Zhao Y, et al. Pre-conceptional intake of folic acid supplements is inversely associated with risk of preterm birth and small-for-gestational-age birth: a prospective cohort study. British Journal of Nutrition. 2016;115(3):509-516. Reproductive BioMedicine Online, Volume 28, Issue 6, 766 - 772

Magnesium depletion undermines healthy aging by disrupting key hallmarks like mitochondrial dysfunction, chronic inflammation, genomic instability, and autophagy, which impair cellular resilience and multisystem longevity. Even beyond specific risks in cardio, metabolic, renal, bone, and neuro categories, mild hypomagnesemia compounds broader age-related vulnerabilities, accelerating frailty and reduced healthspan in older adults. Observational data and mechanistic studies highlight consistent multisystem impacts in elderly individuals with low magnesium.

Research: de Baaij JH, Hoenderop JG, Bindels RJ. Magnesium in man: implications for health and disease. Physiol Rev. 2015 Jan;95(1):1-46. Dominguez LJ, Veronese N, Barbagallo M. Magnesium and the Hallmarks of Aging. Nutrients. 2024 Feb 9;16(4):496. Barbagallo, M., Dominguez, L.J. (2018). Magnesium Role in Health and Longevity. In: Malavolta, M., Mocchegiani, E. (eds) Trace Elements and Minerals in Health and Longevity. Healthy Ageing and Longevity, vol 8. Springer, Cham. Matek Sarić M, Sorić T, Juko Kasap Ž, Lisica Šikić N, Mavar M, Andruškienė J, Sarić A. Magnesium: Health Effects, Deficiency Burden, and Future Public Health Directions. Nutrients. 2025 Nov 20;17(22):3626.

Magnesium depletion can contribute to obesity through disrupted metabolic signaling, insulin sensitivity, and gut microbiota shifts that favor fat storage. Low magnesium impairs energy homeostasis and promotes low-grade inflammation, potentially worsening weight gain in susceptible individuals, especially those with poor diets. Mechanistic and observational links, though not yet confirmed by large RCTs, support monitoring body composition to address this reversible concern.

Research: Al Shammaa A, Al-Thani A, Al-Kaabi M, Al-Saeed K, Alanazi M, Shi Z. Serum Magnesium is Inversely Associated with Body Composition and Metabolic Syndrome. Diabetes Metab Syndr Obes. 2023 Jan 12;16:95-104. Lu L, Chen C, Yang K, Zhu J, Xun P, Shikany JM, He K. Magnesium intake is inversely associated with risk of obesity in a 30-year prospective follow-up study among American young adults. Eur J Nutr. 2020 Dec;59(8):3745-3753. Oliveira AR, Cruz KJ, Severo JS, Morais JB, Freitas TE, Araújo RS, Marreiro DD. Hypomagnesemia and its relation with chronic low-grade inflammation in obesity. Rev Assoc Med Bras (1992). 2017 Feb;63(2):156-163. Cazzola R, Della Porta M, Piuri G, Maier JA. Magnesium: A Defense Line to Mitigate Inflammation and Oxidative Stress in Adipose Tissue. Antioxidants (Basel). 2024 Jul 24;13(8):893.

Zinc deficiency impairs immune defenses by reducing T‑cell activity and weakening resistance to infection. Low zinc levels increase susceptibility to recurrent infections, especially respiratory illnesses such as the common cold, bronchitis, and pneumonia. Clinical studies show that zinc supplementation can strengthen immune response and lower mortality when used alongside standard treatment for severe pneumonia. In a placebo‑controlled trial in elderly participants, zinc supplementation decreased the incidence of infections by 66% and improved cell‑mediated immunity.

Research: Shah UH, Abu-Shaheen AK, Malik MA, Alam S, Riaz M, Al-Tannir MA. The efficacy of zinc supplementation in young children with acute lower respiratory infections: a randomized double-blind controlled trial. Clin Nutr. 2013 Apr;32(2):193-9. Prasad AS. Zinc: role in immunity, oxidative stress and chronic inflammation. Curr Opin Clin Nutr Metab Care. 2009 Nov;12(6):646-52. Wang L, Song Y. Efficacy of zinc given as an adjunct to the treatment of severe pneumonia: A meta-analysis of randomized, double-blind and placebo-controlled trials. Clin Respir J. 2018 Mar;12(3):857-864. Marianna K. Baum, Shenghan Lai, Sabrina Sales, J. Bryan Page, Adriana Campa, Randomized, Controlled Clinical Trial of Zinc Supplementation to Prevent Immunological Failure in HIV-Infected Adults, Clinical Infectious Diseases, Volume 50, Issue 12, 15 June 2010, Pages 1653–1660.

Zinc deficiency during childhood and adolescence is strongly linked to impaired linear growth and delayed sexual maturation, and is a recognized contributor to stunting in many low‑ and middle‑income countries. In some population studies, zinc deficiency has been present in over 30–40% of children, and zinc supplementation programs have been associated with modest but meaningful improvements in height gain over time. Clinically, even marginal zinc deficiency can quietly slow growth velocity and pubertal progression, making adequate zinc intake an important, often overlooked pillar of healthy growth and development.

Research: Abdollahi M, Ajami M, Abdollahi Z, Kalantari N, Houshiarrad A, Fozouni F, Fallahrokni A, Mazandarani FS. Zinc supplementation is an effective and feasible strategy to prevent growth retardation in 6 to 24 month children: A pragmatic double blind, randomized trial. Heliyon. 2019 Nov 1;5(11):e02581. Walravens PA, Krebs NF, Hambidge KM. Linear growth of low income preschool children receiving a zinc supplement. Am J Clin Nutr. 1983 Aug;38(2):195-201. Rerksuppaphol S, Rerksuppaphol L. Zinc supplementation enhances linear growth in school-aged children: A randomized controlled trial. Pediatr Rep. 2018 Jan 4;9(4):7294. Zinc deficiency as risk factor for stunting among children aged 2-5 years. (2017). Universa Medicina, 36(1), 11-18.

Folate deficiency has been associated with a higher risk of depressive symptoms, irritability, and other mood disturbances, likely through its role in one‑carbon metabolism, monoamine neurotransmitter synthesis, and methylation processes in the brain. Clinical and epidemiologic studies have found that people with low folate or elevated homocysteine are more likely to experience major depression, and lower folate status has been linked to poorer response to certain antidepressant medications. The encouraging clinical point is that, in folate‑deficient individuals, correcting folate status (often with folic acid or methylfolate, and alongside vitamin B12 when indicated) may improve mood symptoms and, in some cases, enhance antidepressant treatment response, especially when combined with comprehensive psychiatric and lifestyle interventions.

Research: David Mischoulon, Maurizio Fava. Folate in Depression: Efficacy, Safety, Differences in Formulations, and Clinical Issues. The Journal of Clinical Psychiatry. 2009. Gao S, Khalid A, Amini-Salehi E, Radkhah N, Jamilian P, Badpeyma M, Zarezadeh M. Folate supplementation as a beneficial add-on treatment in relieving depressive symptoms: A meta-analysis of meta-analyses. Food Sci Nutr. 2024 Mar 8;12(6):3806-3818. Reynolds EH, Crellin R, Bottiglieri T, Laundy M, Toone BK, et al. Methylfolate as Monotherapy in Depression. A Pilot Randomised Controlled Trial. J Neurol Psychol. 2015;3(1): 5. Reynolds EH. Folic acid, ageing, depression, and dementia. BMJ. 2002 Jun 22;324(7352):1512-5. Gilbody S, Lightfoot T, Sheldon T. Is low folate a risk factor for depression? A meta-analysis and exploration of heterogeneity. J Epidemiol Community Health. 2007 Jul;61(7):631-7.

CoQ10 deficiency is a recognized cause of progressive cerebellar ataxia with cerebellar atrophy, often beginning in childhood or early adulthood and frequently accompanied by seizures, peripheral neuropathy, and cognitive or psychiatric changes. Case series and larger cohorts show that many patients with primary CoQ10 deficiency have prominent cerebellar atrophy on MRI and mixed neurologic features, and in some reports seizures occurred in roughly one‑third of affected individuals. The hopeful aspect is that, unlike many hereditary ataxias, early and sustained CoQ10 supplementation has led to meaningful improvement or stabilization of gait, strength, and seizure control in a substantial subset of patients, which is why CoQ10 deficiency is emphasized as a treatable cause of cerebellar ataxia that should not be missed.

Research: Lamperti C, Naini A, Hirano M, De Vivo DC, Bertini E, Servidei S, Valeriani M, Lynch D, Banwell B, Berg M, Dubrovsky T, Chiriboga C, Angelini C, Pegoraro E, DiMauro S. Cerebellar ataxia and coenzyme Q10 deficiency. Neurology. 2003 Apr 8;60(7):1206-8. Artuch R, Brea-Calvo G, Briones P, Aracil A, Galván M, Espinós C, Corral J, Volpini V, Ribes A, Andreu AL, Palau F, Sánchez-Alcázar JA, Navas P, Pineda M. Cerebellar ataxia with coenzyme Q10 deficiency: diagnosis and follow-up after coenzyme Q10 supplementation. J Neurol Sci. 2006 Jul 15;246(1-2):153-8. Hirano M, Quinzii C, DiMauro S. Restoring balance to ataxia with coenzyme Q10 deficiency. Journal of the Neurological Sciences, 246, 11-12. Naini A, Lewis VJ, Hirano M, DiMauro S. Primary coenzyme Q10 deficiency and the brain. Biofactors. 2003;18(1-4):145-52.

Potassium deficiency can progress from diffuse muscle weakness to flaccid paralysis, and in severe hypokalemia this paralysis may involve the diaphragm and other respiratory muscles, resulting in hypoventilation and acute respiratory failure. In these situations, patients often present with ascending weakness, areflexia, and shortness of breath or an inability to take a deep breath, and may require urgent ventilatory support while intravenous potassium is carefully replaced. Case reports and cohort data show that even admission potassium values just below the normal range are associated with a higher risk of needing mechanical ventilation in hospitalized patients, underscoring the importance of promptly recognizing and correcting hypokalemia before it reaches paralysis‑level severity.

Research: Sobrosa P Sr, Ferreira Â, Vilar da Mota R, Couto J, Sousa L. Severe Hypokalemia and Respiratory Muscle Paralysis: An Atypical Manifestation of Primary Sjögren's Syndrome. Cureus. 2024 Dec 23;16(12):e76240. Alemu GK, Asfaw SA, Asres LS, Kassa BY. Severe Life-Threatening Hypokalemia Primarily Presented With Isolated Paralysis: Case Series From Ethiopia. Clin Case Rep. 2025 Jan 6;13(1):e70062. Pande AR, Rai N, Manchanda S, Srivastava A, Agarwal S, Srivastava IC, Awasthi A. The Critical Care Phenotype of Hypokalemic Paralysis: Etiology, Outcomes, and Predictors of Respiratory Failure in a Retrospective Cohort Study. Cureus. 2026 Feb 18;18(2):e103865. Gombar S, Mathew PJ, Gombar KK, D'Cruz S, Goyal G. Acute respiratory failure due to hypokalaemic muscular paralysis from renal tubular acidosis. Anaesth Intensive Care. 2005 Oct;33(5):656-8.

Zinc deficiency often first shows up on the skin, with acrodermatitis‑like eruptions around the mouth, perineum, and distal extremities, accompanied by alopecia and sometimes nail changes. Characteristic lesions can be erythematous, scaly, or pustular, and both congenital and acquired zinc deficiency states have been reported to improve dramatically within days to weeks of adequate zinc repletion. Clinically, zinc is also crucial for normal collagen synthesis and immune function in the skin, so deficiency is linked to delayed wound healing and weaker scars, whereas restoring zinc status can enhance re‑epithelialization and reduce wound complications.

Research: Kelly S, Stelzer JW, Esplin N, Farooq A, Karasik O. Acquired Acrodermatitis Enteropathica: A Case Study. Cureus. 2017 Sep 8;9(9):e1667. Alwadany MM, Al Wadani AF, Almarri FH, Alyami HS, Al-Subaie MA. Acrodermatitis Enteropathica: A Rare Case With Lifelong Implications. Cureus. 2023 Apr 18;15(4):e37783. Al-Khafaji Z, Brito S, Bin BH. Zinc and Zinc Transporters in Dermatology. Int J Mol Sci. 2022 Dec 18;23(24):16165. Ogawa Y, Kinoshita M, Shimada S, Kawamura T. Zinc and Skin Disorders. Nutrients. 2018 Feb 11;10(2):199.

Folate (folic acid) deficiency impairs DNA synthesis in rapidly dividing cells, which leads to megaloblastic anemia characterized by enlarged red blood cells, fatigue, pallor, and sometimes shortness of breath. Population studies have shown that folate deficiency and macrocytosis can be present for months before overt symptoms appear, and in some cohorts, up to roughly one quarter of anemic adults had an underlying folate or B12 deficiency rather than iron deficiency alone. The encouraging clinical point is that, once identified, folate‑responsive megaloblastic anemia often improves within weeks of adequate folic acid repletion, with reticulocyte counts rising in about 5–7 days and hemoglobin recovering more gradually over several weeks.

Research: Koury MJ, Price JO, Hicks GG. Apoptosis in megaloblastic anemia occurs during DNA synthesis by a p53-independent, nucleoside-reversible mechanism. Blood. 2000 Nov 1;96(9):3249-55. Daniel S. Socha, MD, Sherwin I. DeSouza, MD, Aron Flagg, MD, Mikkael Sekeres, MD, MS and Heesun J. Rogers, MD, PhD. Severe megaloblastic anemia: Vitamin deficiency and other causes. Cleveland Clinic Journal of Medicine March 2020, 87 (3) 153-164. H.B. Castellanos-Sinco, et al. Megaloblastic anaemia: Folic acid and vitamin B12 metabolism. Revista Médica del Hospital General de México. Vol. 78. Issue 3. Pages 105-150 (July - September 2015). Anis Hariz, et al. Megaloblastic Anemia. StatPearls April 3, 2023.

In some adolescents and adults, CoQ10 deficiency presents as an isolated mitochondrial myopathy with exercise intolerance, early fatigue, and proximal muscle weakness rather than a full multisystem syndrome. Muscle biopsies in these patients often show reduced CoQ10 content and ragged‑red fibers or other mitochondrial changes, even when brain, heart, and kidneys appear largely spared on standard evaluation. The encouraging piece is that many individuals with CoQ10‑deficient myopathy experience noticeable improvements in exercise capacity, muscle strength, and CK levels after several months of adequately dosed CoQ10 supplementation, highlighting the importance of recognizing this treatable cause of mitochondrial muscle disease early.

Research: Lalani SR, Vladutiu GD, Plunkett K, Lotze TE, Adesina AM, Scaglia F. Isolated Mitochondrial Myopathy Associated With Muscle Coenzyme Q10 Deficiency. Arch Neurol. 2005;62(2):317–320. Neergheen V, Chalasani A, Wainwright L, et al. Coenzyme Q10 in the Treatment of Mitochondrial Disease. Journal of Inborn Errors of Metabolism and Screening. 2017;5Sacconi S, Trevisson E, Salviati L, Aymé S, Rigal O, Redondo AG, Mancuso M, Siciliano G, Tonin P, Angelini C, Auré K, Lombès A, Desnuelle C. Coenzyme Q10 is frequently reduced in muscle of patients with mitochondrial myopathy. Neuromuscul Disord. 2010 Jan;20(1):44-8. Quinzii CM, Hirano M. Coenzyme Q and mitochondrial disease. Dev Disabil Res Rev. 2010;16(2):183-8.

In many patients, inadequate zinc status affects the gastrointestinal tract, contributing to chronic or recurrent diarrhea, anorexia, and characteristic changes in taste (hypogeusia) and smell (hyposmia) that further suppress intake. Clinical studies in children with acute and persistent diarrhea have shown that zinc supplementation shortens illness duration and reduces subsequent diarrheal episodes, underscoring how low zinc status both results from and perpetuates gut losses. The practical implication is that, when patients present with otherwise unexplained diarrhea, poor appetite, and altered taste or smell, especially in the setting of malabsorption, restrictive diets, or chronic illness, evaluating and correcting zinc deficiency can be an important step in breaking this cycle and restoring nutritional and gastrointestinal health.

Research: Mozaffar B, Ardavani A, Muzafar H, Idris I. The Effectiveness of Zinc Supplementation in Taste Disorder Treatment: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Nutr Metab. 2023 Mar 8;2023:6711071. Heckmann SM, Hujoel P, Habiger S, Friess W, Wichmann M, Heckmann JG, Hummel T. Zinc gluconate in the treatment of dysgeusia--a randomized clinical trial. J Dent Res. 2005 Jan;84(1):35-8. Mahajan SK, Prasad AS, Lambujon J, Abbasi AA, Briggs WA, McDonald FD. Improvement of uremic hypogeusia by zinc: a double-blind study. Am J Clin Nutr. 1980 Jul;33(7):1517-21. Aliani M, Udenigwe CC, Girgih AT, Pownall TL, Bugera JL, Eskin MN. Zinc deficiency and taste perception in the elderly. Crit Rev Food Sci Nutr. 2013;53(3):245-50. Tanaka H, Mori E, Yonezawa N, Sekine R, Nagai M, Tei M, Otori N. Efficacy of Normalising Serum Zinc Level for Patients with Olfactory Dysfunction and Zinc Deficiency. ORL J Otorhinolaryngol Relat Spec. 2024;86(2):73-81.

In the gums and supporting tissues around the teeth, low CoQ10 levels have been linked to worse periodontal inflammation and deeper pocketing, likely because CoQ10 is essential for local mitochondrial energy production and antioxidant defense. Small human studies have found that people with periodontitis often have reduced CoQ10 in gingival tissue or crevicular fluid, and that topical or oral CoQ10 used alongside standard scaling and root planing can modestly improve measures such as bleeding on probing and pocket depth. The practical implication is that maintaining adequate CoQ10 status may help support healthier periodontal tissues and could be a useful adjunctive strategy, particularly in individuals with chronic gum disease or high oxidative stress in the oral cavity.

Research: Prakash S, Sunitha J, Hans M. Role of coenzyme Q(10) as an antioxidant and bioenergizer in periodontal diseases. Indian J Pharmacol. 2010 Dec;42(6):334-7. R. Nakamura, G.P. Littarru, K. Folkers, & E.G. Wilkinson. Study of CoQ10-Enzymes in Gingiva from Patients with Periodontal Disease and Evidence for a Deficiency of Coenzyme Q10*, Proc. Natl. Acad. Sci. U.S.A. 71 (4) 1456-1460. Ali K. Barakat et.al. Clinical Evaluation of Co-enzyme Q10 in Management of Chronic Periodontitis Patients: Mouth Split Study. International Journal of Health Sciences & Research. Vol.9; Issue: 1; January 2019.